Anxiety is the most common mental health condition in the United States, and the medications used to treat it fall into two very different families. One is the modern first-line choice — the SSRIs and SNRIs prescribed for long-term management. The other is the benzodiazepines, an older, faster-acting class that carries a very different risk profile. The statistics describing how often each is used are scattered across several federal surveys that were never designed to line up, and reading them well means keeping their methods straight.
If you or someone you know is struggling or in crisis, help is available. Call or text 988 to reach the 988 Suicide & Crisis Lifeline, available 24/7.
This is a descriptive summary of the data, not medical advice. Two things make anxiety medication statistics unusually easy to misread. First, the two most-cited benzodiazepine prevalence numbers come from completely different measurement methods and cannot be blended into a single trend. Second, no primary federal source publishes a clean “share of people with anxiety who take medication” — so any figure claiming to be that number is almost certainly manufactured. This article lays out what the sources actually say. For the broader clinical overview, see our anxiety pillar page.
SSRIs and SNRIs Are the First-Line Medications
For generalized anxiety disorder and other anxiety disorders, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the recommended first-line pharmacologic treatment (Strawn et al., 2018). They are favored over benzodiazepines for ongoing management because they are effective for the sustained, excessive worry that defines these conditions and do not carry the same dependence and overdose concerns.
In clinical trials, roughly 60–75% of patients respond to SSRIs for anxiety disorders (Garakani et al., 2020). “Response” in trial terms means a clinically meaningful reduction in symptoms, not necessarily full remission, and it typically takes several weeks to appear. That distinction matters: the same features that make SSRIs the long-term choice — a gradual onset and no acute sedative effect — are why they are not used for immediate symptom relief the way benzodiazepines sometimes are.
Because these medications are also widely prescribed for depression, pain, and sleep, general antidepressant-use statistics do not isolate anxiety treatment. For the full breakdown of how many adults take antidepressants and why the measures differ, see our companion piece on antidepressant usage statistics.
Benzodiazepine Use: Two Non-Comparable Measures
Benzodiazepines are the class most people picture when they think of “anti-anxiety medication,” but pinning down how common their use is depends entirely on which survey you read. The two authoritative primary numbers are built on different foundations — one is a self-report of any use, the other is a pharmacy-based count of prescribed use — and they are not two readings of the same thing.
| Measure | Method | Population | Prevalence | Source & year |
|---|---|---|---|---|
| Any past-year benzodiazepine use | NSDUH self-report | Adults 18+ | 12.6% (30.6 million) | Maust et al., 2015–2016 |
| — used as prescribed | NSDUH self-report | Adults 18+ | 10.4% (25.3 million) | Maust et al., 2015–2016 |
| — misuse | NSDUH self-report | Adults 18+ | 2.2% (5.3 million) | Maust et al., 2015–2016 |
| Prescribed annual use | MEPS pharmacy-based | Adults 18+ | 4.7% → 3.4% | Olfson et al., 2018–2022 |
The self-report figure comes from the National Survey on Drug Use and Health: about 12.6% of adults (30.6 million) reported using a benzodiazepine in the past year, split into 10.4% (25.3 million) who used them as prescribed and 2.2% (5.3 million) who misused them (Maust et al., 2015–2016). This captures any use a person recalls, including borrowed or misused pills, which is why it runs high.
The pharmacy-based figure comes from the Medical Expenditure Panel Survey (MEPS), which counts prescriptions actually filled. By that method, prescribed benzodiazepine use fell from 4.7% of adults in 2018 to 3.4% in 2022, with the steepest decline among adults 56 and older (Olfson et al., 2026). This is a genuine downward trend within a single consistent method — but it sits far below the 12.6% NSDUH number because it counts something narrower. The gap between 12.6% and 3.4% is a difference in measurement, not a collapse in use. Do not read them as one trend.
Older Adults
Benzodiazepine use is a particular focus among older adults, where the risks of falls, cognitive effects, and drug interactions are higher. According to MEPS data, 4.0% of adults 65 and older used benzodiazepines only (without opioids) in 2021–2022 (AHRQ, 2024). The MEPS trend above showing the sharpest prescribing declines among adults 56 and older reflects a deliberate clinical push to reduce these prescriptions in exactly this group. For more context on this population, see our older adults page.
The Symptom Backdrop: The 2024 GAD-7 Screen
To read medication numbers in context, it helps to know how many people are experiencing anxiety symptoms in the first place. The most current national measure comes from the 2024 NSDUH, which applied the GAD-7 symptom screen rather than a full diagnosis (SAMHSA, 2024):
| Group | Moderate/severe symptoms (past 2 weeks) | Breakdown |
|---|---|---|
| Adults 18+ | 7.4% | 4.7% moderate, 2.7% severe |
| Adolescents 12–17 | 18.8% | — |
This is a symptom-severity screen over a two-week window, not a diagnosis, so it should not be lined up against older diagnostic prevalence figures as though anxiety rates had changed. It simply establishes the scale of recent symptoms. For how this screen fits alongside the older diagnostic estimates, see our anxiety statistics 2026 roundup and the deeper breakdown in how many people have anxiety.
What No Primary Source Tells Us
Here is the number that does not exist: a clean, nationally representative figure for the share of people with anxiety who receive medication. No primary federal source publishes it. The surveys that measure anxiety symptoms and the surveys that measure medication use are different instruments with different samples, and neither was built to produce that ratio. Any article presenting a tidy “X% of anxiety patients are on medication” statistic is extrapolating beyond what the data supports.
The closest legitimate proxy is far broader: in 2024, 52.1% of adults with any mental illness received any mental health treatment (SAMHSA, 2024) — a category that spans therapy and medication across all conditions, not anxiety specifically. It is a useful directional benchmark, but it is not an anxiety-medication rate, and it should be labeled as what it is. The honest summary is that the coverage question for anxiety medication remains unanswered in the primary data.
The Overdose Risk Behind the Benzodiazepine Numbers
The reason benzodiazepine prescribing has drawn scrutiny — and the reason SSRIs are preferred first-line — is visible in the overdose data. In 2023, 10,870 overdose deaths involved benzodiazepines, and nearly 70% of those also involved illicitly manufactured fentanyl (NIDA, 2025). That co-involvement is the dominant story of recent benzodiazepine deaths: the danger is concentrated where benzodiazepines are combined, often unknowingly, with potent illicit opioids.
The longer trend shows how sharply the risk climbed. The benzodiazepine-involved overdose death rate rose from 0.46 per 100,000 in 2000 to 3.55 per 100,000 in 2017 — nearly an eightfold increase (Kleinman & Weiss, 2022). Benzodiazepines taken alone carry real risks of dependence and withdrawal, but the fatal overdose picture is overwhelmingly one of combination with opioids and other central nervous system depressants. This is the clinical logic behind the measured decline in prescribing captured in the MEPS data, and behind the first-line status of SSRIs and SNRIs. For related context on overdose patterns, see our panic disorder page and substance use disorder overview.
Reading Anxiety Medication Data Well
Three rules keep this topic honest. First, SSRIs and SNRIs are the first-line medications, with roughly 60–75% trial response rates, and general antidepressant statistics do not isolate anxiety use. Second, the two benzodiazepine prevalence numbers — 12.6% self-reported past-year use versus 3.4–4.7% pharmacy-confirmed prescribed use — come from different methods and must never be merged into a single trend. Third, no primary source gives a clean share of people with anxiety who take medication, and the benzodiazepine overdose risk is driven largely by fentanyl co-involvement. For how anxiety fits into the wider national picture, see our national overview.
Frequently Asked Questions
What is the first-line medication for anxiety?
SSRIs and SNRIs are the recommended first-line pharmacologic treatment for generalized anxiety disorder and other anxiety disorders (Strawn et al., 2018). In trials, roughly 60–75% of patients respond to SSRIs (Garakani et al., 2020), though a meaningful response typically takes several weeks to develop.
How common is benzodiazepine use in the US?
It depends on the measure. By self-report, about 12.6% of adults (30.6 million) used a benzodiazepine in the past year (Maust et al., 2015–2016). By pharmacy-based prescription data, prescribed use was lower and falling — 4.7% of adults in 2018 down to 3.4% in 2022 (Olfson et al., 2026). The two figures come from different methods and are not directly comparable.
Is benzodiazepine use going up or down?
Within the pharmacy-based MEPS measure, prescribed benzodiazepine use declined from 4.7% (2018) to 3.4% (2022) of adults, with the steepest drop among adults 56 and older (Olfson et al., 2026). That is a real trend within one consistent method, but it cannot be compared to the higher self-report figure from a different survey.
What share of people with anxiety take medication?
No primary federal source publishes a clean figure for this. The closest broader proxy is that 52.1% of adults with any mental illness received any mental health treatment in 2024 (SAMHSA, 2024), which covers all conditions and both therapy and medication — not anxiety medication specifically.
How dangerous are benzodiazepines?
In 2023, benzodiazepines were involved in 10,870 overdose deaths, with nearly 70% also involving illicitly manufactured fentanyl (NIDA, 2025). The overdose death rate rose from 0.46 per 100,000 in 2000 to 3.55 in 2017 (Kleinman & Weiss, 2022). Most fatal outcomes involve combination with opioids or other depressants rather than benzodiazepines alone.
Why are SSRIs preferred over benzodiazepines?
SSRIs and SNRIs are effective for the sustained worry that defines anxiety disorders and do not carry the dependence or overdose risks associated with benzodiazepines, which is why they are the first-line choice for long-term management (Strawn et al., 2018).
Sources
- Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for Generalized Anxiety Disorder in Adults and Pediatric Patients. PMC; 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/
- Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. PMC; 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7786299/
- Maust DT, Lin LA, Blow FC. Benzodiazepine Use and Misuse Among Adults in the United States. Psychiatr Serv. 2019. https://pubmed.ncbi.nlm.nih.gov/30554562/
- Olfson M, et al. Trends in Benzodiazepine Prescribing in the United States, 2018–2022 (MEPS). 2026. https://pubmed.ncbi.nlm.nih.gov/41734365/
- Agency for Healthcare Research and Quality. Benzodiazepine Use Among Older Adults. MEPS Statistical Brief No. 567. AHRQ; 2024. https://meps.ahrq.gov/data_files/publications/st567/stat567.shtml
- Substance Abuse and Mental Health Services Administration. Release of the 2024 NSDUH. SAMHSA; 2025. https://www.samhsa.gov/blog/release-2024-nsduh-leveraging-latest-substance-use-mental-health-data-make-america-healthy-again
- National Institute on Drug Abuse. Drug Overdose Death Rates (analysis of CDC WONDER). NIDA; 2025. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
- Kleinman RA, Weiss RD. Benzodiazepine-Involved Overdose Deaths in the USA, 2000–2019. PMC; 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9198172/